Mediwound Ltd. (MDWD) 7.22 $MDWD
MediWound's (MDWD) CEO Paul Thomas on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 12, 12:23PM CST
MDWD: 7.22 (+0.17)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 11:45AM CST
CERU: 6.62 (-0.06), TBIO: 2.91 (+0.01), FXEN: 1.99 (+0.10), TRIP: 84.81 (+2.41), STMP: 56.92 (-0.24), ZEN: 25.38 (+1.02), OWW: 11.68 (-0.04), PME: 2.42 (-0.07), OESX: 4.15 (-0.01), GENE: 8.04 (+1.90), BG: 82.22 (+1.78), ARCI: 2.53 (-0.01), NTWK: 5.14 (-0.11), BASI: 2.06 (+0.18), EXPE: 89.49 (-0.08), MDWD: 7.22 (+0.17), SCOR: 53.35 (-1.10), LTRPA: 31.12 (+0.77), DWSN: 6.89 (-0.42), ZU: 14.22 (-0.30)
MediWound misses by $0.07, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 6:48AM CST
MDWD: 7.22 (+0.17)
MediWound Reports Fourth Quarter and Year End 2014 Financial Results
Business Wire - Thu Feb 12, 6:02AM CST
MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today reported financial results for the three and 12 months ended December 31, 2014.
MDWD: 7.22 (+0.17)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 4:30PM CST
NLSN: 45.59 (+2.02), RTIX: 5.54 (+0.19), AAP: 150.16 (-1.26), JAH: 51.18 (+0.18), LMNS: 10.80 (+0.57), THS: 80.00 (-1.57), RWLK: 17.40 (-0.77), CAB: 53.55 (+1.23), FAF: 37.00 (+0.10), HSP: 87.35 (unch), PNK: 25.64 (-0.35), MFA: 7.89 (unch), SPW: 87.37 (-2.81), MFC: 17.31 (+0.27), HIMX: 8.04 (+0.28), LNCE: 30.72 (-0.25), TIME: 24.84 (+0.35), AVP: 9.08 (+0.39), INCY: 75.94 (+0.28), NNN: 41.00 (+0.20), NWE: 53.61 (-0.85), COR: 48.08 (+1.08), MHFI: 102.19 (unch), NCI: 14.99 (-0.01), BWA: 60.17 (-1.21), HERO: 0.92 (+0.02), NRP: 7.86 (-0.45), STC: 37.85 (+0.23), AB: 27.17 (+0.47), CPLA: 65.23 (-1.37), TU: 34.83 (+0.01), IFF: 116.96 (+2.19), GNC: 48.11 (-0.55), MINI: 40.62 (-0.83), ACOR: 36.14 (-0.51), CVE: 19.42 (-0.29), SNI: 73.00 (+0.39), CCE: 43.69 (-0.66), K: 63.20 (-0.10), DPS: 76.95 (-1.35), BG: 82.22 (+1.78), AAWW: 48.01 (+0.44), Q: 63.31 (+0.06), SHPG: 239.82 (+6.11), MANU: 17.20 (-0.21), MPEL: 27.54 (+0.78), APA: 67.05 (+2.47), DBD: 35.82 (+1.07), MPW: 14.64 (+0.14), HE: 33.14 (-0.22), RYN: 28.02 (-1.15), CS: 23.65 (+0.23), PDS: 6.04 (+0.12), ANR: 1.27 (+0.03), SON: 46.65 (-0.79), SKYW: 13.84 (+1.88), LPNT: 69.04 (-0.06), RDN: 16.10 (-0.43), MDWD: 7.22 (+0.17), SCOR: 53.35 (-1.10), FLO: 21.68 (+0.38)
MediWound to Host Fourth Quarter and Year End 2014 Financial Results Conference Call on February 12, 2015 at 8:30 a.m. Eastern Time
GlobeNewswire - Fri Feb 06, 7:16AM CST
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results for the three and twelve months ended December 31, 2014, at 7:00 a.m. Eastern time on February 12, 2014.
MDWD: 7.22 (+0.17)
MediWound Ltd. (Nasdaq: MDWD) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Wed Feb 04, 9:00AM CST
What:
MDWD: 7.22 (+0.17), NDAQ: 49.48 (-0.27)
MediWound to Ring the NASDAQ Stock Market Closing Bell on February 5, 2015 in Recognition of Burn Awareness Week
GlobeNewswire - Wed Feb 04, 7:00AM CST
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Gal Cohen, MediWound's Chief Executive Officer, will ring the NASDAQ Stock Market Closing Bell on February 5, 2015 in recognition of the American Burn Association's Burn Awareness Week taking place from February 1-7, 2015.
MDWD: 7.22 (+0.17)
MediWound to distribute NexoBrid in Mexico through COVALEO SA
M2 - Wed Jan 21, 6:04AM CST
Biopharmaceutical company MediWound (Nasdaq:MDWD) reported on Tuesday the launch of an agreement to grant the exclusive rights to market and distribute NexoBrid in Mexico for the treatment of severe burns.
MDWD: 7.22 (+0.17)
MediWound Expands Distribution of NexoBrid to Mexico through Agreement with COVALEO SA
Business Wire - Tue Jan 20, 7:01AM CST
MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announced today the signing of an agreement granting COVALEO SA de CV exclusive rights to market and distribute NexoBrid(R) in Mexico for the treatment of severe burns. Severe burns are primarily treated at approximately 20 hospitals and burn centers in Mexico.
MDWD: 7.22 (+0.17)
MediWound Ltd. (MDWD) in Focus: Stock Jumps 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 8:18AM CST
MediWound Ltd. (MDWD) was a big mover last session, as the company saw its shares rise around 6% on the day.
APRI: 1.84 (-0.08), MDWD: 7.22 (+0.17)
MediWound to Present at Oppenheimer 25th Annual Healthcare Conference
Business Wire - Tue Dec 09, 8:01AM CST
MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Company management will participate at the Oppenheimer 25th Annual Healthcare Conference taking place from December 10-11, 2014 in New York City. Gal Cohen, President and Chief Executive Officer of MediWound, will be presenting a corporate overview on Thursday, December 11th at 3:20 p.m. Eastern time.
MDWD: 7.22 (+0.17)
5 Stocks Ready for Breakouts: MediWound and More
at The Street - Thu Dec 04, 8:44AM CST
These are the stocks that often go on to make monster moves to the upside.
NAME: 8.17 (+0.25), KRA: 20.16 (+0.19), MDWD: 7.22 (+0.17), TRNX: 25.32 (+0.12), JD: 26.23 (-0.27)
MediWound to Present at Two Upcoming Investor Conferences
Business Wire - Thu Nov 06, 7:01AM CST
MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that MediWound's management team will be presenting the Company's corporate overview at the following investor conferences in November.
MDWD: 7.22 (+0.17)
MediWound EPS in-line
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:32PM CST
MDWD: 7.22 (+0.17)
MediWound Reports Third Quarter 2014 Financial Results
Business Wire - Wed Nov 05, 3:00PM CST
MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today reported financial results for the three and nine months ended September 30, 2014.
MDWD: 7.22 (+0.17)
MediWound Initiates Post-Marketing Study with NexoBrid(R) to Treat Severe Burns in Pediatric Patients
Business Wire - Mon Nov 03, 6:30AM CST
MediWound Ltd. (Nasdaq: MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company has commenced a European post-marketing (Phase 3) Pediatric Investigation Plan (PIP) study to evaluate the efficacy and safety of NexoBrid(R) as a treatment for severe burns in children. MediWound is conducting this study as part of the European legislation concerning the development and authorization of medicines for use in children in Europe.
MDWD: 7.22 (+0.17)
MediWound reports November 5
Seeking Alpha - at Seeking Alpha - Sat Nov 01, 5:06PM CDT
MDWD: 7.22 (+0.17)
MediWound to Host Third Quarter 2014 Financial Results Conference Call on November 5, 2014 at 4:30 p.m. Eastern Time
Business Wire - Wed Oct 29, 6:00AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results for the three and nine months ended September 30, 2014, after the market close on Wednesday, November 5, 2014.
MDWD: 7.22 (+0.17)
MediWound's NexoBrid to be Featured at International Society for Burn Injuries 2014
GlobeNewswire - Tue Oct 07, 8:12AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company's NexoBrid(R) will be featured in multiple oral and poster presentations at the 17 Congress of the International Society for Burn Injuries (ISBI) taking place October 12-16, 2014 in Sydney, Australia. The presentation abstracts will be available online at www.isbi.org.
MDWD: 7.22 (+0.17)
MediWound's (MDWD) CEO Paul Thomas on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 12, 12:23PM CST
MDWD: 7.22 (+0.17)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 11:45AM CST
CERU: 6.62 (-0.06), TBIO: 2.91 (+0.01), FXEN: 1.99 (+0.10), TRIP: 84.81 (+2.41), STMP: 56.92 (-0.24), ZEN: 25.38 (+1.02), OWW: 11.68 (-0.04), PME: 2.42 (-0.07), OESX: 4.15 (-0.01), GENE: 8.04 (+1.90), BG: 82.22 (+1.78), ARCI: 2.53 (-0.01), NTWK: 5.14 (-0.11), BASI: 2.06 (+0.18), EXPE: 89.49 (-0.08), MDWD: 7.22 (+0.17), SCOR: 53.35 (-1.10), LTRPA: 31.12 (+0.77), DWSN: 6.89 (-0.42), ZU: 14.22 (-0.30)
MediWound misses by $0.07, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 6:48AM CST
MDWD: 7.22 (+0.17)
MediWound Reports Fourth Quarter and Year End 2014 Financial Results
Business Wire - Thu Feb 12, 6:02AM CST
MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today reported financial results for the three and 12 months ended December 31, 2014.
MDWD: 7.22 (+0.17)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 4:30PM CST
NLSN: 45.59 (+2.02), RTIX: 5.54 (+0.19), AAP: 150.16 (-1.26), JAH: 51.18 (+0.18), LMNS: 10.80 (+0.57), THS: 80.00 (-1.57), RWLK: 17.40 (-0.77), CAB: 53.55 (+1.23), FAF: 37.00 (+0.10), HSP: 87.35 (unch), PNK: 25.64 (-0.35), MFA: 7.89 (unch), SPW: 87.37 (-2.81), MFC: 17.31 (+0.27), HIMX: 8.04 (+0.28), LNCE: 30.72 (-0.25), TIME: 24.84 (+0.35), AVP: 9.08 (+0.39), INCY: 75.94 (+0.28), NNN: 41.00 (+0.20), NWE: 53.61 (-0.85), COR: 48.08 (+1.08), MHFI: 102.19 (unch), NCI: 14.99 (-0.01), BWA: 60.17 (-1.21), HERO: 0.92 (+0.02), NRP: 7.86 (-0.45), STC: 37.85 (+0.23), AB: 27.17 (+0.47), CPLA: 65.23 (-1.37), TU: 34.83 (+0.01), IFF: 116.96 (+2.19), GNC: 48.11 (-0.55), MINI: 40.62 (-0.83), ACOR: 36.14 (-0.51), CVE: 19.42 (-0.29), SNI: 73.00 (+0.39), CCE: 43.69 (-0.66), K: 63.20 (-0.10), DPS: 76.95 (-1.35), BG: 82.22 (+1.78), AAWW: 48.01 (+0.44), Q: 63.31 (+0.06), SHPG: 239.82 (+6.11), MANU: 17.20 (-0.21), MPEL: 27.54 (+0.78), APA: 67.05 (+2.47), DBD: 35.82 (+1.07), MPW: 14.64 (+0.14), HE: 33.14 (-0.22), RYN: 28.02 (-1.15), CS: 23.65 (+0.23), PDS: 6.04 (+0.12), ANR: 1.27 (+0.03), SON: 46.65 (-0.79), SKYW: 13.84 (+1.88), LPNT: 69.04 (-0.06), RDN: 16.10 (-0.43), MDWD: 7.22 (+0.17), SCOR: 53.35 (-1.10), FLO: 21.68 (+0.38)
MediWound to Host Fourth Quarter and Year End 2014 Financial Results Conference Call on February 12, 2015 at 8:30 a.m. Eastern Time
GlobeNewswire - Fri Feb 06, 7:16AM CST
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results for the three and twelve months ended December 31, 2014, at 7:00 a.m. Eastern time on February 12, 2014.
MDWD: 7.22 (+0.17)
MediWound Ltd. (Nasdaq: MDWD) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Wed Feb 04, 9:00AM CST
What:
MDWD: 7.22 (+0.17), NDAQ: 49.48 (-0.27)
MediWound to Ring the NASDAQ Stock Market Closing Bell on February 5, 2015 in Recognition of Burn Awareness Week
GlobeNewswire - Wed Feb 04, 7:00AM CST
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Gal Cohen, MediWound's Chief Executive Officer, will ring the NASDAQ Stock Market Closing Bell on February 5, 2015 in recognition of the American Burn Association's Burn Awareness Week taking place from February 1-7, 2015.
MDWD: 7.22 (+0.17)
MediWound to distribute NexoBrid in Mexico through COVALEO SA
M2 - Wed Jan 21, 6:04AM CST
Biopharmaceutical company MediWound (Nasdaq:MDWD) reported on Tuesday the launch of an agreement to grant the exclusive rights to market and distribute NexoBrid in Mexico for the treatment of severe burns.
MDWD: 7.22 (+0.17)
MediWound Expands Distribution of NexoBrid to Mexico through Agreement with COVALEO SA
Business Wire - Tue Jan 20, 7:01AM CST
MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announced today the signing of an agreement granting COVALEO SA de CV exclusive rights to market and distribute NexoBrid(R) in Mexico for the treatment of severe burns. Severe burns are primarily treated at approximately 20 hospitals and burn centers in Mexico.
MDWD: 7.22 (+0.17)
MediWound Ltd. (MDWD) in Focus: Stock Jumps 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 8:18AM CST
MediWound Ltd. (MDWD) was a big mover last session, as the company saw its shares rise around 6% on the day.
APRI: 1.84 (-0.08), MDWD: 7.22 (+0.17)
MediWound to Present at Oppenheimer 25th Annual Healthcare Conference
Business Wire - Tue Dec 09, 8:01AM CST
MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Company management will participate at the Oppenheimer 25th Annual Healthcare Conference taking place from December 10-11, 2014 in New York City. Gal Cohen, President and Chief Executive Officer of MediWound, will be presenting a corporate overview on Thursday, December 11th at 3:20 p.m. Eastern time.
MDWD: 7.22 (+0.17)
5 Stocks Ready for Breakouts: MediWound and More
at The Street - Thu Dec 04, 8:44AM CST
These are the stocks that often go on to make monster moves to the upside.
NAME: 8.17 (+0.25), KRA: 20.16 (+0.19), MDWD: 7.22 (+0.17), TRNX: 25.32 (+0.12), JD: 26.23 (-0.27)
MediWound to Present at Two Upcoming Investor Conferences
Business Wire - Thu Nov 06, 7:01AM CST
MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that MediWound's management team will be presenting the Company's corporate overview at the following investor conferences in November.
MDWD: 7.22 (+0.17)
MediWound EPS in-line
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:32PM CST
MDWD: 7.22 (+0.17)
MediWound Reports Third Quarter 2014 Financial Results
Business Wire - Wed Nov 05, 3:00PM CST
MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today reported financial results for the three and nine months ended September 30, 2014.
MDWD: 7.22 (+0.17)
MediWound Initiates Post-Marketing Study with NexoBrid(R) to Treat Severe Burns in Pediatric Patients
Business Wire - Mon Nov 03, 6:30AM CST
MediWound Ltd. (Nasdaq: MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company has commenced a European post-marketing (Phase 3) Pediatric Investigation Plan (PIP) study to evaluate the efficacy and safety of NexoBrid(R) as a treatment for severe burns in children. MediWound is conducting this study as part of the European legislation concerning the development and authorization of medicines for use in children in Europe.
MDWD: 7.22 (+0.17)
MediWound reports November 5
Seeking Alpha - at Seeking Alpha - Sat Nov 01, 5:06PM CDT
MDWD: 7.22 (+0.17)
MediWound to Host Third Quarter 2014 Financial Results Conference Call on November 5, 2014 at 4:30 p.m. Eastern Time
Business Wire - Wed Oct 29, 6:00AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release financial results for the three and nine months ended September 30, 2014, after the market close on Wednesday, November 5, 2014.
MDWD: 7.22 (+0.17)
MediWound's NexoBrid to be Featured at International Society for Burn Injuries 2014
GlobeNewswire - Tue Oct 07, 8:12AM CDT
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company's NexoBrid(R) will be featured in multiple oral and poster presentations at the 17 Congress of the International Society for Burn Injuries (ISBI) taking place October 12-16, 2014 in Sydney, Australia. The presentation abstracts will be available online at www.isbi.org.
MDWD: 7.22 (+0.17)
